Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Tarlock

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Blood Advances|May 3, 2021
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemiaAllison J Kaeding, Sonali P Barwe, Anilkumar Gopalakrishnapillai, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Blood Advances|September 21, 2021
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomesBenjamin J Huang, Jenny L Smith, Yi-Cheng Wang, et al.
Nature Communications|September 19, 2022
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemiaBenjamin J Huang, Jenny L Smith, Jason E Farrar, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Blood Advances|May 3, 2021
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemiaAllison J Kaeding, Sonali P Barwe, Anilkumar Gopalakrishnapillai, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Blood Advances|September 21, 2021
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomesBenjamin J Huang, Jenny L Smith, Yi-Cheng Wang, et al.
Nature Communications|September 19, 2022
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemiaBenjamin J Huang, Jenny L Smith, Jason E Farrar, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 5